Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
Yukio Hosomi(Tokyo Metropolitan Komagome Hospital), Akihiko Gemma(Nippon Medical School), Kunihiko Kobayashi(Harbin Medical University), Koichi Minato, Akira Inoue(Tohoku University Hospital), Toshiyuki Harada(Hokkaido hospital), Kei Takamura(Obihiro Kosei General Hospital), Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Shunichi Sugawara(Sendai Kousei Hospital), Kazuhisa Takahashi(Kansai Medical University), Terufumi Kato(Taipei Veterans General Hospital), Satoshi Morita(Kyoto University), Yuka Fujita, Koichi Hagiwara(Hokkaido University Hospital), Toshihiro Nukiwa(Tohoku University)
Cited by 483
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k